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CONCLUSIONS
Androgen-deprivation therapy boosts MX1 expression,
a silent effector against COVID-19.
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Cancer is a risk factor for SARS-CoV-2 infection. Recent reports have shown that prostate
cancer (PCa) patients who underwent androgen-deprivation therapies (ADT) were partially
protected from COVID-19. The human myxovirus resistance gene 1 (MX1) is expressed in many
tissues, including prostate, and we have previously demonstrated its antitumoral activity in PCa,
tilting the balance of endoplasmic reticulum stress towards pro-death events. Another key aspect
of this protein is its participation in the antiviral response. It is recognized as an IFN-stimulated
gene (ISGs), especially during influenza virus infection. Currently, there are several ongoing
clinical trials for COVID-19 prevention and/or treatment using type I or III interferons. However,
IFN administration could enhance a "cytokine-storm" causing a hyper-inflammatory response and
contributing to multiple organ failure. In this work we used a published case-control study
(GSE152075) from SARS-CoV-2 positive (n=403) and negative patients (n=50) to analyze the
response to infection assessing gene expression profiles of key host cell receptors and antiviral
proteins. Additionally, given that MX1 was differentially expressed between COVID-19 and non-
COVID-19 patients, we evaluated MX1 expression in A549 and Calu3 lung cell lines and ferrets
infected with SARS-CoV-2. Since ADT seems to reduce SARS-CoV-2 infection incidence, we
aimed to study MX1 regulation by dihydrotestosterone (DHT). We browsed publicly available
ChIP-seq experiments evaluating androgen receptor (AR) binding sites in MX1 promoter and
coding region in different PCa cell lines under DHT stimulation; and we treated LNCaP cells with
DHT to assess MX1 expression under androgen stimulation. Finally, using transcriptomics data
from PCa patients under ADT, we studied how androgen ablation regulates MX1 expression.
SUMMARY
RESULTS
1. Expression of host cell receptor genes in COVID-19 and non-COVID-19 
patients
2. Expression of host antiviral effector genes in COVID-19 and non-COVID-19 
patients.
Gene expression analysis for host cell receptor genes: A) ACE2, B) TMPRSS2, C) BSG/CD147, D) CTSB, E) CTSL and
F) ADAM17. I) COVID-19 vs. non-COVID-19 patients (P-values correspond to Wilcoxon rank sum test); II) COVID-19 and
non-COVID-19 patients by sex (P-values correspond to Wilcoxon rank sum test); III) COVID-19 and non-COVID-19
patients categorized by age groups (P-values correspond to decreasing Jonckheere-Terpstrata trend test). Data was
obtained from (GSE152075). Statistical significance was set at P < 0.05.
Gene expression analysis for key antiviral genes: A) MX1, B) MX2, C) NRF2, D) IRF3, E) HIF1A and F) HMOX1. I)
COVID-19 vs. non-COVID-19 patients (P-values correspond to Wilcoxon rank sum test), II) COVID-19 and non-COVID-19
patients by sex (P-values correspond to Wilcoxon rank sum test), and III) COVID-19 and non-COVID-19 patients
categorized by age groups (P-values correspond to decreasing Jonckheere-Terpstrata trend test). Data was obtained from
(GSE152075). Statistical significance was set at P < 0.05.
3. Principal component analysis in SARS-CoV-2 positive and negative patients
A) Principal Component Analysis biplot of gene expression data showing a roughly segregation of non-COVID-19 and
COVID-19 patients stratified by low (Ct>24), medium (Ct=24-19) and high (Ct<19; blue) viral load. Each point represents
one individual, and the arrows depict the gene expression profile; black arrows show the 4 genes that have the greatest
weight in driving the difference between the groups. B) Forest plots representing multivariable regression analysis. Model
I) considering as covariates: individual gene expression, viral load and age; and model II) considering as covariates: viral
load, age, and all genes.
5. Analysis of MX1 expression by SARS-CoV2 infection in lung cell lines
A) Dot plots showing MX1 mRNA expression levels in A549 (n = 6) and Calu-3 (n = 6) human cell lines comparing SARS-
CoV-2 infection vs. mock infection. B) Dot plots depicting MX1 expression in tracheal biopsy samples (n = 7) from SARS-
CoV-2 infected vs. mock-treated ferrets. Samples were collected on day 3 after SARS-CoV-2 infection. Expression data
was obtained from the GSE147507 dataset. For all graphs, the mean is represented as a horizontal line. Statistical
significance *P < 0.05, **P < 0.01.
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6. MX1 expression modulation by androgen
A) Androgen receptor (AR) binding sites in MX1 from ChIP-seq datasets GSE66037, GSE28950 and GSE108704. ChIP-
seq reads for dihydrotestosterone (DHT), bicalutamide, ethanol (EtOH) or control treatments are represented as blue
boxes. B) MX1 mRNA expression assessed by RT-qPCR in LNCaP cell line under dihydrotestosterone (DHT) treatment or
PBS as control. C) Plot comparing MX1 mRNA expression in locally-advanced/metastatic PCa patients paired samples
before (red) and after (green) androgen-deprivation therapy (ADT) from the merged GSE51005 and GSE48403 datasets
(n = 11). Statistical significance: *P < 0.05, ** P < 0.01.
Our study shows differences in ACE2, MX1, MX2 and BSG/CD147 expression between
COVID-19 and non-COVID-19 patients and point out to MX1 as a critical responder in SARS-
CoV-2 infection. Furthermore, we demonstrated MX1 modulation by ADT. Taking into
consideration the fact that PCa patients that underwent ADT were less prone to
present the infection, we propose this gene as an alternative druggable target for













A) Principal Component Analysis (PCA) biplot of gene expression data showing a roughly segregation of non-COVID-19
and COVID-19 samples. Each point represents one individual, and the arrows depict the gene expression profile; black
arrows show the 4 genes that have the greatest weight in driving the difference between the groups. B) 3D-scatter plots
for I) ACE2, MX1, and BSG/CD147 and II) ACE2, MX2, and BSG/CD147.
4. Association between SARS-CoV-2 viral load and gene expression
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